Form 4: Esperion CFO Discloses Planned Stock Sale for Tax Obligations Under 10b5-1 Plan
Insider Transaction Report
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, reported a planned sale of 11 common shares on July 17, 2025, at $1.115 per share to cover tax obligations on vested restricted stock units.
Summary
- Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc. (ESPR), reported a transaction involving the company's common stock.
- On July 17, 2025, 11 shares of common stock are planned to be sold at a price of $1.115 per share.
- The sale is designated to satisfy tax obligations on vested restricted stock units.
- This transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
- Following this planned transaction, Benjamin Halladay will beneficially own 474,462 shares of common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned sale to cover tax obligations on vested equity, which is a neutral event and does not indicate positive or negative sentiment about the company's prospects or financial health.
Future Outlook
No forward-looking statements or guidance regarding the company's financial performance or strategic direction are provided in this filing, as it pertains solely to an insider's personal stock transaction.
Management Comments
- Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Industry Context
This filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy/Procedure Documentation | Benjamin Halladay, Chief Financial Officer, granted a Limited Power of Attorney on November 16, 2022, to Sheldon Koenig and Benjamin Looker. This power of attorney authorizes them to execute and file various U.S. Securities and Exchange Commission (SEC) forms, including Form ID, Form 3, Form 4, Form 5, and Schedule 13D, on his behalf. | 2022-11-16 | This delegation streamlines the process for timely and accurate SEC filings related to insider beneficial ownership, enhancing compliance efficiency and ensuring adherence to Section 16 of the Securities Exchange Act of 1934. |
Stakeholder Impact
- Minimal impact on shareholders as this is a small, routine, tax-related sale by an executive, not indicative of a change in company fundamentals or executive confidence. The transaction is pre-planned under a 10b5-1 plan, further reducing its perceived significance.
Key Dates
| Date | Description |
|---|---|
| 2022-11-16 | Date Benjamin Halladay granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker for SEC filings. |
| 2025-07-17 | Date of the planned common stock transaction by Benjamin Halladay. |
| 2025-07-18 | Date the Form 4 was signed and filed by power of attorney. |
Keywords
Esperion Therapeutics, ESPR, Form 4, Insider Transaction, Benjamin Halladay, Chief Financial Officer, Stock Sale, Tax Obligation, Restricted Stock Units, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.